SCHEMBL5128065

SCHEMBL5128065

CCc1cccc(CNC[C@H](C(N)Cc2cc(F)cc(F)c2)[C@H](Sc2nnc(-c3ccccc3)o2)C(=O)O)c1.NC(=O)c1c(NC(=O)CCC(=O)O)sc2c1CCCC2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.40
MAPT P10636 8/20 0.39
MEN1 O00255 6/20 0.39
KMT2A Q03164 6/20 0.39
POLB P06746 4/20 0.39
HPGD P15428 4/20 0.39
HSD17B10 Q99714 3/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 7/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HTT P42858 1/20 0.36
CASP6 P55212 1/20 0.36
CNR2 P34972 1/20 0.36
TP53 P04637 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5128063 0.92 MAPT (0.42) FLT3MAPTMEN1KMT2APOLB
SCHEMBL5579546 0.83 BACE1 (0.41) POLBLMNATP53
SCHEMBL5579547 0.83 BACE1 (0.41) POLBLMNATP53
SCHEMBL5579544 0.83 BACE1 (0.41) POLBLMNATP53
SCHEMBL5579626 0.77 FLT3 (0.46) FLT3MAPTMEN1KMT2APOLB
SCHEMBL5579615 0.77 FLT3 (0.46) FLT3MAPTMEN1KMT2APOLB
SCHEMBL6698958 0.76 BACE1 (0.51) FLT3MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL5130125 0.71 FLT3 (0.47) FLT3MAPTMEN1KMT2APOLB
SCHEMBL5128057 0.68 FLT3 (0.39) FLT3MAPTMEN1KMT2APOLB
SCHEMBL5579816 0.66 BACE1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 FLT3 4248/4885MAPT 246/4885MEN1 1613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.